Abatacept in ANCA Associated Vasculitis

NCT00482066 ↗

Phase 2 Terminated 7 enrolled Imperial College London Bristol-Myers Squibb · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.

Timeline

Start: 2007-11
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Abatacept	Other / unclassified	500 mg	Intravenous
Comparator	Abatacept	Other / unclassified	750 mg	Intravenous
Comparator	Abatacept	Other / unclassified	1 g	Intravenous

Abatacept in ANCA Associated Vasculitis

Summary

Timeline

Drugs

Indications